To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

June 30, 2026

Conditions
Amyotrophic Lateral Sclerosis
Interventions
DRUG

HK-001

HK-001 is synthesized by PharmaCore Biotech Co., Ltd. Synthetic (Z)-BP with high purity will be used in this proposed study.

DRUG

Placebo control

In order to evaluate the safety and tolerability of HK-001 more accurately, a drug-free placebo control is planned to be utilized for the same administration route in this proposed trial. The placebo control that is identical in appearance, smell, weight, and excipients will be supplied by Everfront Biotech Inc.

Trial Locations (1)

97002

Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien City

All Listed Sponsors
lead

Everfront Biotech Co., Ltd.

INDUSTRY

NCT03651349 - To Determine the Maximum Tolerated Dose (MTD) of HK-001 in Healthy Volunteers | Biotech Hunter | Biotech Hunter